Cover Image
市場調查報告書

纖維症:開發中產品分析

Fibrosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255947
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
纖維症:開發中產品分析 Fibrosis - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 132 Pages
簡介

所謂纖維症,是指肌肉纖維間的疤痕組織過度產生纖維帶的狀態。纖維性疤痕組織是為了填補肌肉受損後,損傷的肌肉空間而產生的,以提供再生肌肉纖維粘附的表面積。由疤痕組織組成的結締組織細胞無法收縮和鬆弛。纖維症異常發達會引起肌肉無力和疲勞,無法進行活動。治療包括抗纖維化劑和手術。

本報告提供全球纖維症治療藥的開發趨勢調查,提供開發中產品的各開發階段的比較分析,藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,該部門的最新趨勢,主要企業的檢討等資訊。

簡介

  • 調查範圍

纖維症;概要

纖維症 - 治療藥的開發

  • 開發中產品的概要
  • 企業開發中的治療藥
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 各大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Acceleron Pharma Inc
  • Aelis Farma SAS
  • Allakos Inc
  • Anima Biotech Ltd
  • Bristol-Myers Squibb Company
  • Calypso Biotech SA
  • Complexa Inc
  • Encycle Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Five Prime Therapeutics Inc
  • Genfit SA
  • GlycoMimetics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • iBio Inc
  • Immunomet Therapeutics Inc
  • Inception Sciences Inc
  • Insmed Inc
  • Inventiva
  • Ironwood Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Lycera Corp
  • Neumedicines Inc
  • Novartis AG
  • Palatin Technologies Inc
  • Ribomic Inc
  • Scholar Rock Inc
  • SciFluor Life Sciences LLC
  • SK Chemicals Co Ltd
  • UCB SA
  • VivaCell Biotechnology Espana SL

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9136IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibrosis - Overview
    • Fibrosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fibrosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibrosis - Companies Involved in Therapeutics Development
    • Acceleron Pharma Inc
    • Aelis Farma SAS
    • Allakos Inc
    • Anima Biotech Ltd
    • Bristol-Myers Squibb Company
    • Calypso Biotech SA
    • Complexa Inc
    • Encycle Therapeutics Inc
    • F. Hoffmann-La Roche Ltd
    • Five Prime Therapeutics Inc
    • Genfit SA
    • GlycoMimetics Inc
    • Hanmi Pharmaceuticals Co Ltd
    • iBio Inc
    • Immunomet Therapeutics Inc
    • Inception Sciences Inc
    • Insmed Inc
    • Inventiva
    • Ironwood Pharmaceuticals Inc
    • Isarna Therapeutics GmbH
    • Lycera Corp
    • Neumedicines Inc
    • Novartis AG
    • Palatin Technologies Inc
    • Ribomic Inc
    • Scholar Rock Inc
    • SciFluor Life Sciences LLC
    • SK Chemicals Co Ltd
    • UCB SA
    • VivaCell Biotechnology Espana SL
  • Fibrosis - Drug Profiles
    • ACE-2798 - Drug Profile
    • AEF-0118 - Drug Profile
    • AK-002 - Drug Profile
    • Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile
    • CALY-001 - Drug Profile
    • CWHM-12 - Drug Profile
    • elafibranor - Drug Profile
    • G-XXX - Drug Profile
    • IB-DMD - Drug Profile
    • IBIOCFB-03 - Drug Profile
    • IM-156 - Drug Profile
    • INS-1007 - Drug Profile
    • ISTH-1106 - Drug Profile
    • IW-1701 - Drug Profile
    • IW-1973 - Drug Profile
    • LYC-53976 - Drug Profile
    • Monoclonal Antibodies for Fibrosis - Drug Profile
    • Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile
    • Monoclonal Antibody 2 for Fibrosis - Drug Profile
    • Monoclonal Antibody for Fibrotic Scar - Drug Profile
    • Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile
    • NCE-401 - Drug Profile
    • Neumomir - Drug Profile
    • NMIL-121 - Drug Profile
    • OCX-063 - Drug Profile
    • PAT-048 - Drug Profile
    • PL-5028 - Drug Profile
    • PRI-724 - Drug Profile
    • Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile
    • RBM-003 - Drug Profile
    • RBM-007 - Drug Profile
    • Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile
    • Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
    • RG-6125 - Drug Profile
    • Small Molecule for Fibrosis - Drug Profile
    • Small Molecule for Fibrosis - Drug Profile
    • Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile
    • Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile
    • Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile
    • Small Molecules for Fibrosis - Drug Profile
    • Small Molecules for Fibrosis - Drug Profile
    • Small Molecules for Fibrosis - Drug Profile
    • Small Molecules for Fibrosis - Drug Profile
    • Small Molecules for Fibrosis - Drug Profile
    • Small Molecules for Fibrosis - Drug Profile
    • Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile
    • Small Molecules for Fibrosis and Oncology - Drug Profile
    • Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile
    • Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile
    • Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile
    • Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile
    • Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile
    • SRI-31277 - Drug Profile
    • ST-2001 - Drug Profile
    • Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile
    • VCE-0048 - Drug Profile
    • X-165 - Drug Profile
    • XOMA-089 - Drug Profile
  • Fibrosis - Dormant Projects
  • Fibrosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Fibrosis - Pipeline by Acceleron Pharma Inc, H1 2017
  • Fibrosis - Pipeline by Aelis Farma SAS, H1 2017
  • Fibrosis - Pipeline by Allakos Inc, H1 2017
  • Fibrosis - Pipeline by Anima Biotech Ltd, H1 2017
  • Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Fibrosis - Pipeline by Calypso Biotech SA, H1 2017
  • Fibrosis - Pipeline by Complexa Inc, H1 2017
  • Fibrosis - Pipeline by Encycle Therapeutics Inc, H1 2017
  • Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Fibrosis - Pipeline by Five Prime Therapeutics Inc, H1 2017
  • Fibrosis - Pipeline by Genfit SA, H1 2017
  • Fibrosis - Pipeline by GlycoMimetics Inc, H1 2017
  • Fibrosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Fibrosis - Pipeline by iBio Inc, H1 2017
  • Fibrosis - Pipeline by Immunomet Therapeutics Inc, H1 2017
  • Fibrosis - Pipeline by Inception Sciences Inc, H1 2017
  • Fibrosis - Pipeline by Insmed Inc, H1 2017
  • Fibrosis - Pipeline by Inventiva, H1 2017
  • Fibrosis - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
  • Fibrosis - Pipeline by Lycera Corp, H1 2017
  • Fibrosis - Pipeline by Neumedicines Inc, H1 2017
  • Fibrosis - Pipeline by Novartis AG, H1 2017
  • Fibrosis - Pipeline by Palatin Technologies Inc, H1 2017
  • Fibrosis - Pipeline by Ribomic Inc, H1 2017
  • Fibrosis - Pipeline by Scholar Rock Inc, H1 2017
  • Fibrosis - Pipeline by SciFluor Life Sciences LLC, H1 2017
  • Fibrosis - Pipeline by SK Chemicals Co Ltd, H1 2017
  • Fibrosis - Pipeline by UCB SA, H1 2017
  • Fibrosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
  • Fibrosis - Dormant Projects, H1 2017
  • Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top